Q2 2022

Filed Aug 15, 2022 · 10-Q · 46 days after period end · 0001477932-22-006064

Q2 2022 · 10-Q

Revenue

$5.00K

+150.0% vs Q2 2021

Net Income

-$926.00K

N/M vs Q2 2021

EPS Diluted

-$0.04

N/M vs Q2 2021

Gross Profit$4,000+100.0%

Operating Income

Same quarter

Metric	Q2 2022	Q2 2021	Q2 2020	Q2 2019
Revenue	$5.00K	$2.00K	$0.00	$1.00K
Net Income	-$926.00K	-$1.03M	-$6.75M	-$2.66M
EPS Diluted	-$0.04	-$0.09	-$0.57	-$0.81

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR